title: Multicenter clinical experience using an erbium:YAG laser for vitreoretinal surgery.
abstract: OBJECTIVE
  To evaluate the advantages, disadvantages, safety, complications, and surgical applicability of an erbium:YAG laser system for maneuvers in vitreoretinal surgery.
  
  
  METHODS
  A prospective, consecutive trial of 68 eyes in 66 patients undergoing vitreoretinal surgery in which an erbium:YAG laser with graduated output from 0.2 to 5.0 mJ per pulse, repetition rate of 2 to 30 Hz, and equipped with a flexible fiber optic and interchangeable 20-gauge intraocular fiber optic endoprobes was used to perform specific maneuvers, including transection, incision, and ablation of membranes, retinotomy, vessel coagulation, iridectomy, and lens tissue ablation. The patients were treated in five centers in contemporary vitreoretinal surgical settings for surgical indications, including proliferative diabetic retinopathy, proliferative vitreoretinopathy, epiretinal membrane, and retinopathy of prematurity.
  
  
  RESULTS
  One hundred seventy-four maneuvers were performed with an overall surgical efficacy rating of excellent or good in 84% of maneuvers, ranging from a high of 100% for subretinal membrane transection to a low of 25% for coagulation of blood vessels. Complications included retinal break or photocoagulative injury in 5% of epiretinal membrane incisions, minor bleeding from transected retinal vessels during 29% of retinotomies, and intraocular lens damage during two posterior capsulotomies. The most significant limitation was the cautious pace used during maneuvers near the retinal surface.
  
  
  CONCLUSIONS
  The erbium:YAG laser is capable of versatile new approaches offering precise tissue cutting and ablation in vitreoretinal surgical maneuvers with a high degree of safety. The main limitation encountered was the slow speed of certain critical maneuvers near the retina.
authors.affiliation: Massachusetts Eye and Far Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: D'Amico
authors.forename: M S
authors.initials: MS
authors.lastname: Blumenkranz
authors.forename: M J
authors.initials: MJ
authors.lastname: Lavin
authors.forename: H
authors.initials: H
authors.lastname: Quiroz-Mercado
authors.forename: I G
authors.initials: IG
authors.lastname: Pallikaris
authors.forename: G R
authors.initials: GR
authors.lastname: Marcellino
authors.forename: G E
authors.initials: GE
authors.lastname: Brooks
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005128:Eye Diseases / Q000601:surgery; D005260:Female; D005336:Fiber Optic Technology; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects / Q000379:methods; D008297:Male; D008875:Middle Aged; D055100:Optical Fibers; D011183:Postoperative Complications; D011446:Prospective Studies; D012164:Retinal Diseases / Q000601:surgery*; D012449:Safety; D014792:Visual Acuity; D014822:Vitreous Body / Q000601:surgery*